Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
NCT ID: NCT05424523
Last Updated: 2022-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2021-02-25
2021-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
NCT00079937
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
NCT00546143
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
NCT01976208
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
NCT01328886
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
NCT00482508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omalizumab
Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
Omalizumab
Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omalizumab
Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with allergic asthma and could be treated using omalizumab. Comorbidities included allergic rhinitis, atopic dermatitis, nasal polyp, chronic urticaria, and food allergy
* Received omalizumab during the identification period
* Had at least one documented follow-up data after omalizumab treatment
* Provided informed consent if required by ethics committee (EC) of hospital
Exclusion Criteria
6 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
East Hanover, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CIGE025BCN01 from the Novartis Clinical Trials Results Database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIGE025BCN01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.